Drug Database
Back to search

Poland· PL-100332940

Moventig

A naloxegol product containing naloxegolum, registered in Poland by Gruenenthal GmbH. The same ATC class is registered in 15 of our 19 countries.

ATC A06AH03

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedMoventigATCA06AH03REGISTER NO.PL-100332940PACKS LISTED1CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about naloxegolumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Naloxegol is registered in 15 of 19 countries.

Countries holding a registration under ATC A06AH03 (naloxegol), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 10 of them publish a price we can compare per daily dose
Search naloxegol products by name

Naloxegol · ATC A06AH03

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of naloxegol costs, country by country.

Normalised to the WHO defined daily dose (25 mg), the median price runs from $3.62 in Italy to $5.84 in Spain — a ×1.6 gap.

  • 4 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Naloxegol · price per daily dose (25 mg)

USD · FX 28 Sept 2026

  • ES Spain$5.84
  • CH Switzerland$5.75
  • FR France$3.80
  • IT Italy$3.62
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Naloxegolum
Manufacturer
Gruenenthal GmbH
Country
Poland (PL)
ATC code
A06AH03
ATC class
Naloxegol
Defined daily dose
25 mg, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    05902135480045

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

204 interactions on record for naloxegol.

Graded by severity as the source publishes them — 66 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check naloxegol against other medicinesHow interaction checks work

Naloxegol · interactions on record

204 records

  • 66 severe
  • 57 moderate
  • 81 minor

Most severe, free to view

  • AprepitantA04AD12severe
  • DanazolG03XA01severe
  • LonafarnibA16AX20severe
  • BerotralstatB06AC06severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Naloxegol in 10 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All naloxegol products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • United Kingdom (Northern Ireland) · Moventig
  • Iceland · Moventig
  • Liechtenstein · Moventig
  • Norway · Moventig

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/973299e3-9784-4af1-a49e-6cb68320b1fc
GET /v1/drugs/973299e3-9784-4af1-a49e-6cb68320b1fc?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "25 mg",
  "packaging": "Rp ¦ EU/1/14/962/004 ¦ 106002\n10 tabl.\n05902135480045 ¦ Rp ¦ EU/1/14/962/005 ¦ 106003\n30 tabl.\nRp ¦ EU/1/14/962/007 ¦ 106004\n90 tabl. w blistrze perforowanym\nRp ¦ EU/1/14/962/006 ¦ 106005\n90 tabl. w blistrze\nRp ¦ EU/1/14/962/009 ¦ 131743\n10 tabl. w blistrze perforowanym\nRp ¦ EU/1/14/962/010 ¦ 131744\n30 tabl. w blistrze perforowanym\nRp ¦ EU/1/14/962/011 ¦ 131745\n100 tabl. w blistrze perforowanym",
  "substance": "Naloxegolum 25 mg",
  "common_name": "Naloxegolum",
  "pl_product_id": "100332940",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about naloxegol.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console